Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| BMRN - Biomarin Pharmaceutical | 14.89% | Reduce −3.7% | 2,061,373 | $82.87 | $171M | −78,241 | +$6M |
| UTHR - United Therapeutics | 13.04% | Reduce −2.8% | 634,806 | $235.64 | $150M | −18,273 | +$32M |
| Abiomed | 10.67% | Hold | 494,397 | $247.51 | $122M | — | — |
| INSM - Insmed | 10.04% | Reduce −0.7% | 5,840,398 | $19.72 | $115M | −40,901 | −$23M |
| FOLD - Amicus | 9.22% | Reduce −0.6% | 9,847,774 | $10.74 | $106M | −55,987 | +$12M |
| Staar Surgical | 6.84% | Reduce −2.7% | 1,106,567 | $70.93 | $78M | −30,401 | −$12M |
| BIIB - Biogen | 6.42% | Hold | 360,981 | $203.94 | $74M | — | — |
| Revance Therapeutics | 5.31% | Reduce −0.2% | 4,405,039 | $13.82 | $61M | −10,650 | −$25M |
| PRTA - Prothena | 3.98% | Hold | 1,681,477 | $27.15 | $46M | — | — |
| Sage Therapeutics | 2.40% | Reduce 0.0% | 851,409 | $32.30 | $28M | −310 | −$691K |
| VNDA - Vanda Pharmaceuticals | 2.37% | Hold | 2,491,200 | $10.90 | $27M | — | — |
| Karyopharm Therapeutics | 2.21% | Hold | 5,621,533 | $4.51 | $25M | — | — |
| ACAD - Acadia Pharmaceuticals | 2.06% | Reduce −25.5% | 1,678,196 | $14.09 | $24M | −573,638 | −$31M |
| ALKS - Alkermes | 1.57% | Reduce −10.4% | 603,400 | $29.79 | $18M | −70,171 | +$253K |
| EHTH - Ehealth | 1.35% | Add +0.1% | 1,654,693 | $9.33 | $15M | +2,433 | −$5M |
| Gossamer Bio | 1.28% | Reduce −0.3% | 1,750,651 | $8.37 | $15M | −6,106 | −$596K |
| SNDX - Syndax Pharmaceuticals | 1.03% | Hold | 612,600 | $19.24 | $12M | — | — |
| ALGN - Align Technology | 0.91% | Hold | 44,305 | $236.68 | $10M | — | — |
| Epizyme | 0.87% | Hold | 6,774,541 | $1.47 | $10M | — | — |
| ANAB - Anaptysbio | 0.76% | Hold | 431,024 | $20.30 | $9M | — | — |
| Clovis Oncology | 0.70% | Hold | 4,473,967 | $1.80 | $8M | — | — |
| Gritstone Oncology | 0.49% | Hold | 2,330,504 | $2.42 | $6M | — | — |
| Kezar Life Sciences | 0.47% | Hold | 656,200 | $8.27 | $5M | — | — |
| CYTK - Cytokinetics | 0.38% | Hold | 111,717 | $39.29 | $4M | — | — |
| TVTX - Travere Therapeutics | 0.35% | Hold | 166,069 | $24.23 | $4M | — | — |
| MIRM - Mirum Pharmaceuticals | 0.11% | Hold | 64,700 | $19.46 | $1M | — | — |
| Alimera Sciences | 0.10% | Hold | 200,919 | $5.47 | $1M | — | — |
| NVAX - Novavax | 0.06% | Hold | 12,500 | $51.44 | $643K | — | — |
| ALDX - Aldeyra Therapeutics | 0.06% | Hold | 160,800 | $3.99 | $642K | — | — |
| Magenta Therapeutics | 0.05% | Hold | 432,300 | $1.20 | $519K | — | — |
| URGN - Urogen Pharma | 0.02% | Hold | 24,500 | $8.20 | $201K | — | — |
| Holding | 0.02% | Hold | 27,100 | $7.31 | $198K | — | — |
| Marinus Pharmaceuticals | 0.01% | Hold | 31,330 | $4.85 | $152K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals | 0.15% | Exit | 0 | $2.99 | $2M | −652,395 | −$2M |
| Kaleido Biosciences | 0.04% | Exit | 0 | $1.65 | $511K | −309,692 | −$511K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2